AXIOS™ Stent and Electrocautery Enhanced Delivery System. Retrieved from: https://www.bostonscientific.com/en-US/products/stents–gastrointestinal/axios-stent-and-electrocautery-enhanced-delivery-system.html
ERCP is a medical procedure that utilizes endoscopy and fluoroscopy to diagnose, treat, and examine conditions in the liver, gallbladder, bile duct, and pancreas. Typically, an ERCP involves a surgeon and a radiologist working together, with the radiologist directing the endoscopic intervention and scanning for abnormalities. The U.S. ERCP market is poised for significant growth in the coming years, particularly in the biliary and pancreatic stent market, which represents 27% of the total market value. In response to the emergence of exciting new technologies from key players in the ERCP device market, we have decided to explore these companies, their devices, and the technological advancements driving future market growth.
1. Boston Scientific
Boston Scientific Corporation is a global leader in the medical industry that was established by John Able and Pete Nicholas in 1979 as a holding company for Medi-Tech, a medical products company. Boston Scientific is the dominant player in the U.S. ERCP market, leading in all market segments except for the biliary lithotripter market. In 2016, Boston Scientific introduced the AXIOS stent in the biliary and pancreatic stent market, which revolutionized the market and led to a surge in overall growth. The company now maintains a monopoly in the biliary and pancreatic lumen-apposing covered-metal stent market with the AXIOS being the only product available, accounting for over 30% of the total market for biliary and pancreatic stents. As the dominant player in the biliary and pancreatic stent market, commanding over 80% of the market share and a total ERCP market share of just over 75%, Boston Scientific truly cements its position as the clear leader in the industry.
2. Cook Medical
Cook Medical, a global medical device company under Cook Group Inc, specializes in developing, manufacturing, and distributing minimally invasive devices. With a presence in over 100 countries, Cook Medical offers more than 16,000 products. In the U.S. ERCP market, Cook Medical ranks second, holding the second-leading position across all but the smallest segments, where it holds the third-leading position. Cook Medical’s product portfolio includes the Fusion Titan Biliary Dilation Balloon, Memory Basket, and Glo-Tip II Double Lumen ERCP Catheter in the respective markets. With a diversified product portfolio and established customer base, Cook Medical is poised for continued success in the future.
3. CONMED
CONMED, a global medical device company that specializes in various areas of medicine such as orthopedics, laparoscopic, robotic and open surgery, gastroenterology, pulmonology, cardiology, and critical care, has a significant presence in the U.S. ERCP market as the third-largest market share leader. The company has a workforce of over 3,300 employees and markets its products in more than 100 countries worldwide. CONMED’s third-place position is primarily due to its active participation in the biliary and pancreatic stents market, where they held the second-leading position and maintain a sizable share of the market. While the company does not participate in the biliary stone removal basket or the biliary lithotripter market, their high market share in the most significant and fastest-growing segment enables them to maintain their third-highest position, even ahead of Olympus.
In Summary
In conclusion, the U.S. ERCP market is expected to experience significant growth in the coming years, particularly in the biliary and pancreatic stent market. With the emergence of new technologies and devices, the market is becoming more competitive, and companies like Boston Scientific, Cook Medical, and CONMED are leading the way. Boston Scientific, with its dominant market share and innovative AXIOS stent, cements its position as the clear leader in the industry. Cook Medical, with its diverse product portfolio and established customer base, is poised for continued success. Meanwhile, CONMED’s strong presence in the biliary and pancreatic stents market allows them to maintain their third-highest position, ahead of Olympus. As the market continues to grow and evolve, these companies will undoubtedly continue to innovate and drive the industry forward.
If you are wanting to further explore the U.S. ERCP market, visit our U.S. Gastrointestinal Endoscopic devices market report which includes the ERCP segment. Additionally, we have a MedSKU project with a complete brand analysis on ERCP devices and Endo Therapeutics which covers ERCP Guidewires, ERCP Cannulas, Biliary Stone Removal Basket Devices, and many more. View our MedSKU solution below or visit our GI product page at the link above.
